Psoriasis — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDermatopharmacologyPsoriasisSCE Dermatology

A 28-year-old man with plaque psoriasis and concurrent inflammatory bowel disease (Crohn disease) needs biologic therapy. Which biologic class would treat BOTH conditions?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — TNF-alpha inhibitors (Adalimumab/Infliximab) or IL-12/23 inhibitors (Ustekinumab)

TNF-alpha inhibitors (Adalimumab, Infliximab) and Ustekinumab (IL-12/23) are approved for both psoriasis and Crohn disease. This is an important consideration in biologic selection. Crucially, IL-17 inhibitors (Secukinumab, Ixekizumab, Brodalumab) are relatively contraindicated in active IBD as they can trigger or exacerbate Crohn disease. Selective IL-23 inhibitors (Guselkumab, Risankizumab) are approved for psoriasis but Risankizumab has also gained approval for Crohn disease. Biologic selection should account for all comorbidities — psoriasis with IBD, psoriatic arthritis, or uveitis may each favour different agents.

Reference: BAD 2020 Biologic Psoriasis Guidelines; NICE IBD Biologics